COF 003
Alternative Names: COF-003Latest Information Update: 09 Jun 2022
At a glance
- Originator China Oncology Focus Limited
- Developer China Oncology Focus Limited; Lee's Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Cancer
Most Recent Events
- 09 Jun 2022 Preregistration for Cancer in China (unspecified route) before June 2022 (Lee's Pharma pipeline, June 2022)
- 17 Jul 2020 Preclinical trials in Cancer in China (unspecified route) prior to July 2020 (Lee's Pharma pipeline, July 2020)